**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 29-year-old woman developed hepatotoxicity following off-label treatment with hydroxychloroquine for COVID-19.

The woman was hospitalised on 28^th^ March 2020 with severe dyspnoea. Anamnesis revealed that she had given birth through cesarean delivery on 20^th^ March 2020 and later had come in contact with her parents, who had a travel history. Upon current presentation, reverse transcription-polymerase chain reaction (RT-PCR) test revealed positive result for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Her condition deteriorated requiring mechanical ventilation and transfer to ICU. On 30^th^ March 2020 (third day of hospitalisation), she started receiving off-label treatment with piperacillin/tazobactam and azithromycin. On 3rd April 2020 (seventh day of hospitalisation), she started receiving off-label treatment with hydroxychloroquine 400mg twice daily \[*route not stated*\]. One day later, after receiving two doses of hydroxychloroquine, laboratory investigation revealed approximately 10-fold increase in transaminases level.

The woman immediately discontinued hydroxychloroquine therapy. All other medications were continued. Five days after the discontinuation of hydroxychloroquine, her transaminase level decreased to near-normal level. At follow-up, she remained in ICU with progressive improvement in her condition. The hepatotoxicity was considered to have developed secondary to off-label treatment with hydroxychloroquine.
